IV期非小细胞肺癌的全身治疗：美国临床肿瘤学会临床实践指南更新摘要 - Suppr

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

作者信息

Hanna Nasser, Johnson David, Temin Sarah, Masters Gregory

机构信息

Indiana University Simon Cancer Center, Indianapolis, IN; University of Texas Southwestern Medical Center, Dallas, TX; American Society of Clinical Oncology, Alexandria, VA; Helen F. Graham Cancer Center and Research Institute, Newark, DE.

出版信息

J Oncol Pract. 2017 Dec;13(12):832-837. doi: 10.1200/JOP.2017.026716. Epub 2017 Aug 29.

DOI:10.1200/JOP.2017.026716

PMID:28850309

Abstract

摘要

相似文献

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.IV期非小细胞肺癌的全身治疗：美国临床肿瘤学会临床实践指南更新摘要

J Oncol Pract. 2017 Dec;13(12):832-837. doi: 10.1200/JOP.2017.026716. Epub 2017 Aug 29.

ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.伴有致癌驱动基因改变的ROS1重排非小细胞肺癌：关于一些罕见的治疗困境

Clin Lung Cancer. 2018 Jan;19(1):e73-e74. doi: 10.1016/j.cllc.2017.08.005. Epub 2017 Sep 1.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.IV 期非小细胞肺癌的系统治疗：美国临床肿瘤学会临床实践指南更新。

J Clin Oncol. 2017 Oct 20;35(30):3484-3515. doi: 10.1200/JCO.2017.74.6065. Epub 2017 Aug 14.

Recent progress in systemic treatment for lung cancer.肺癌的系统治疗新进展。

Curr Opin Pulm Med. 2018 Jul;24(4):355-366. doi: 10.1097/MCP.0000000000000493.

Predictive markers in lung cancer: a few hints for the practicing pathologist.肺癌中的预测性标志物：给执业病理学家的一些提示。

Pathologica. 2018 Mar;110(1):29-38.

Targeted/emerging therapies for metastatic non-small cell lung cancer.转移性非小细胞肺癌的靶向/新兴疗法。

J Natl Compr Canc Netw. 2015 May;13(5 Suppl):676-8. doi: 10.6004/jnccn.2015.0201.

Molecular Targets Beyond the Big 3.超越“三巨头”的分子靶点。

Thorac Surg Clin. 2020 May;30(2):157-164. doi: 10.1016/j.thorsurg.2020.01.004. Epub 2020 Mar 2.

[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].[晚期非小细胞肺癌预测性生物标志物检测的更新指南：西班牙病理学会和西班牙医学肿瘤学会的全国共识]

Rev Esp Patol. 2020 Jul-Sep;53(3):167-181. doi: 10.1016/j.patol.2019.11.004. Epub 2020 Jun 16.

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I to IIIA Resectable Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary.I至IIIA期可切除非小细胞肺癌的辅助全身治疗和辅助放射治疗：美国临床肿瘤学会/安大略癌症护理临床实践指南更新摘要

J Oncol Pract. 2017 Jul;13(7):449-451. doi: 10.1200/JOP.2017.022251. Epub 2017 Apr 25.

Personalized therapy for lung cancer: striking a moving target.肺癌的个体化治疗：直击移动的目标。

JCI Insight. 2018 Aug 9;3(15). doi: 10.1172/jci.insight.120858.

引用本文的文献

Efficient deep learning model for classifying lung cancer images using normalized stain agnostic feature method and FastAI-2.使用归一化染色无关特征方法和FastAI-2对肺癌图像进行分类的高效深度学习模型

PeerJ Comput Sci. 2025 May 27;11:e2903. doi: 10.7717/peerj-cs.2903. eCollection 2025.

Quality Indicators for Non-Small Cell Lung Cancer in Queensland, Australia, 2012-2021.2012 - 2021年澳大利亚昆士兰州非小细胞肺癌的质量指标

Thorac Cancer. 2025 Mar;16(5):e70034. doi: 10.1111/1759-7714.70034.

[F]F-FAPI-42 PET dynamic imaging characteristics and multiparametric quantification of lung cancer: an exploratory study using uEXPLORER PET/CT.[F]F-FAPI-42 PET对肺癌的动态成像特征及多参数定量分析：一项使用uEXPLORER PET/CT的探索性研究

Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1685-1694. doi: 10.1007/s00259-024-07064-3. Epub 2025 Jan 6.

Osimertinib in Early-Stage EGFR-Mutated Non-small Cell Lung Cancer: A Narrative Review of Its Impact on Survival, Safety, and Clinical Outcomes.奥希替尼用于早期表皮生长因子受体（EGFR）突变的非小细胞肺癌：关于其对生存、安全性和临床结局影响的叙述性综述

Cureus. 2024 Nov 1;16(11):e72862. doi: 10.7759/cureus.72862. eCollection 2024 Nov.

Investigation of the Efficacy of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor in Patients With EGFR Exon 21 L858R Point Mutation-Positive Non-small Cell Lung Cancer.表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂治疗EGFR外显子21 L858R点突变阳性非小细胞肺癌患者的疗效研究

Cureus. 2024 Jul 18;16(7):e64811. doi: 10.7759/cureus.64811. eCollection 2024 Jul.

Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.联合双重检查点免疫治疗与消融性放疗治疗寡转移性非小细胞肺癌的所有部位：1b 期试验的毒性和疗效结果。

Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1481-1489. doi: 10.1016/j.ijrobp.2023.11.040. Epub 2023 Dec 8.

T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study).晚期非小细胞肺癌一线贝伐单抗与表皮生长因子受体酪氨酸激酶抑制剂联合治疗后的T790M检测率（TERRA研究）

Am J Cancer Res. 2023 Jul 15;13(7):3100-3112. eCollection 2023.

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced -Positive NSCLC.一线劳拉替尼对比克唑替尼治疗晚期ALK阳性非小细胞肺癌的随机3期CROWN研究的亚洲亚组分析

JTO Clin Res Rep. 2023 Mar 11;4(5):100499. doi: 10.1016/j.jtocrr.2023.100499. eCollection 2023 May.

Prognostic influence of PD-1/PD-L1 suppressors in combination with chemotherapeutic agents for non-small cell pulmonary carcinoma: system review and meta-analysis.PD-1/PD-L1抑制剂联合化疗药物对非小细胞肺癌的预后影响：系统评价与荟萃分析

Front Oncol. 2023 Apr 19;13:1137913. doi: 10.3389/fonc.2023.1137913. eCollection 2023.

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment.一线纳武利尤单抗-伊匹木单抗联合疗法治疗晚期非小细胞肺癌的成本效益：系统评价与方法学质量评估

Front Health Serv. 2023 Mar 13;3:1034256. doi: 10.3389/frhs.2023.1034256. eCollection 2023.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献